Cellply is a biology-focused deep tech company developing tools to unravel the complexity of the immune system and enable rapid development of new immunotherapies and cell-based therapies with enhanced potency and persistence. The company creates analytical solutions for characterizing therapeutic modalities at single-cell resolution and has developed its flagship product VivaCyte® using patented microfluidic technology, AI-powered automated image analysis, automation, and dedicated software.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €7.15 M | May, 2026 | unspecified |
Industries
Frequently Asked Questions
Where is Cellply located?
Cellply is located in Bologna, Italy.
What industries does Cellply operate in?
Cellply operates in the following industries: biotechnology, deep tech, life sciences, cell therapy, immunotherapy.
How much total funding has Cellply raised?
Cellply has raised a total of $7,150,000.
Who are the investors in Cellply?
The investors in Cellply are: Enea Tech and Biomedical Foundation, CDP Venture Capital.
What does the company Cellply specialize in?
Cellply is a deep tech company that develops automated analytical tools to characterize immune cells at the single-cell level, helping to streamline the development and quality control of cancer cell therapies.
What is the flagship product developed by Cellply?
The flagship product offered by Cellply is called VivaCyte, which is a fully automated, standalone platform designed for rapid potency analysis and immunophenotyping of cell therapies.
How does Cellply technology work?
Cellply uses a combination of patented microfluidic technology, robotics, and AI-powered image analysis to create thousands of miniature co-cultures, allowing for the precise observation and quantification of functional interactions between immune cells and tumor cells.